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Antiretroviral therapy is lifelong and with time carries the risk
of cumulative metabolic and cardiovascular toxicities, the
accumulation of viral resistance mutations, and treatment
fatigue with adherence lapses. The medication is also
expensive. For many patients interruptions are inevitable. This
had led to an interest in the concept of STIs – providing breaks
in therapy in a structured fashion to minimise the long-term
complications of highly active antiretroviral therapy (HAART)
while not compromising the long-term benefits of therapy or
putting patients at risk of immunosuppression-related events
during these breaks. The most popular strategy involves a CD4-
guided strategy to trigger the recommencement of HAART.
STIs are of particular interest for patients who started HAART
with high CD4 counts under previous guidelines, the question
being whether they can safely interrupt their HAART and allow
immunological progression before recommencing.
Major concerns regarding STIs are risk of disease progression
during interruptions resulting in new infections and death,
promotion of viral resistance, and the acute retroviral
syndrome. The latter is a febrile illness similar to
seroconversion illness associated with viral rebound after
stopping HAART. 
Six adult STI studies were reported at CROI from different
settings around the world. The study designs, patient baseline
characteristics and findings differed. The findings of these
studies are summarised in Table I.
THE SMART STUDY1
The Strategies for the Management of Antiretroviral Therapy 
(SMART) study was conducted at 318 sites in 33 countries and
was a prospective randomised trial comparing a virological
suppression (VS) arm (patients stayed on continuous HAART)
to a drug-conservation (DC) arm (in which patients interrupted
or deferred HAART with a CD4 count > 350 cells/µl and
restarted when CD4 dropped below 250 cells/µl). A total of
5 472 patients had been enrolled in the study by the time it
was terminated by the Data Safety Monitoring Board in
January 2006 because of an increased risk of disease
progression and death in the DC arm. The background of the
whole cohort was:
■ median age: 46
■ median CD4 at entry: 598 cells/µl
■ 70% had a viral load (VL) < 400 copies/ml at study entry
■ median CD4 nadir was 253 cells/µl (25% of patients had a
nadir CD4 less than 154 cells/µl)
■ 5% were ART naïve
■ median of 6 years on ART
■ 24% had previously had an AIDS-defining illness. 
The primary endpoint was a combined outcome of death and
disease progression. The rate of this was 3.7/100 person-years
in the DC arm and 1.5/100 person-years in VS arm giving a
relative risk (RR) of 2.5 (95% confidence interval (CI) 1.8 - 3.6).
This difference remained significant when the data were
stratified according to nadir CD4 (even those with a nadir CD4
> 400 cells/µl showed an increased risk of this primary
endpoint in the DC arm). Death was also significantly more
common in the DC  arm (RR 1.9). The CD4-guided strategy to
maintain CD4 > 250 cells/µl and allow STIs was therefore
associated with a greater than 2-fold higher short-term risk of
disease progression and death, despite the fact that patients in
the DC only spent 3% of study follow-up time with a CD4 less
than 200 and 32% of the time with a CD4 less than 350.
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What was surprising, given that STIs would be thought to
reduce drug side-effects by reducing drug exposure, was that
major cardiovascular, hepatic and renal complications were
actually significantly more common in the DC arm (RR 1.4).
ACTG 51702
This study assessed the safety of a single treatment
interruption in a cohort of patients who started HAART with
relatively high CD4 counts under old US guidelines. The
hypothesis was that these patients could safely interrupt
HAART without significant disease progression over 2 years.
There was no control group. In addition the study aimed to
define the parameters that would identify patients in whom
STIs were low risk. Patients in the cohort were on HAART for at
least 6 months with a current and nadir CD4 count > 350
cells/µl and VL < 55 000 copies/ml. HAART was stopped then
recommenced at the discretion of the patient and provider,
STUDY
ANRS 1269 WINDOW-
SMART TRIVICAN ACTG 5170 STACCATO ISS PART ANRS 106
N 5 472 326 167 430 273 403
Setting 33 countries Cote d’Ivoire USA Australia, Italy France
Thailand, 
Switzerland




STI strategy CD4-guided: CD4- guided: CD4-guided: CD4-guided: CT v. 5 CT v. 8-week-on/
Interrupt Interrupt Interrupt Interrupt STIs (defined 8-week-off 
CD4 > 350 CD4 > 350 CD4 > 350 CD4 > 350 time periods of HAART
Restart < 250 Restart < 250 Encouraged to Restart < 350 1 - 3 months)
restart with 
CD4 < 250 
CD4 nadir in 252 272 436 267 418 (mean) 274
STI group
(median)
Follow-up Median Median 96 weeks Median 22 24 months 96 weeks
period 10 months 19 months months 
AIDS or 
death/100 PY
STI 3.7 17.6 2.9 0.2 NR 2 deaths, 0 AIDS
CT 1.5 6.7 – 0.4 NR 0 deaths, 0 AIDS
Main clinical Increased HIV Increased Safe, 5 died Clinically safe 14 serious Clinically and 
outcomes progression serious (none AIDS adverse events immunologically
and death morbidity in related) and in each arm safe
in STI arm STI arm 5 CDC B/C 
events
VL outcome NR NR 20% virological 92% (CT) v. Similar rates of More patients in
failure among 90% (STI) VL failure: the STI arm had 
the 46 who suppressed 24% (CT) v. VL > 400 at 96 
recommenced 26% (STI) weeks (19 v.10%,
HAART p = 0.02)
Resistance NR 11% in STI NR No difference 32% in  STI No difference in
arm v. 5% in between 2 arm mutations
CT arm (NS) arms (2% in demonstrated between 2 arms
each arm) mutation(s) 
during STIs
SE More common No significant NR Diarrhoea, No serious No difference 
in STI arm differences neuropathy adverse events between 2 arms
between 2 arms and lipodystrophy related to
more common drug toxicity
in CT arm
Time off 67% in STI NR Median 96 62% 38% 48.5%
HAART arm v. 7% in weeks
CT arm
RCT = randomised controlled trial; PY = person-years; NR = not reported; CT = continuous treatment; STI = structured treatment interruption; NS = non-significant difference.
TABLE I. ADULT STRUCTURED TREATMENT INTERRUPTION STUDIES REFERRED TO AT CROI 2006
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although recommencement was strongly encouraged when
CD4 dropped below 250 cells/µl. Primary endpoints were time
to Centers for Disease Control (CDC) B or C event or death or
CD4 < 250 cells/µl or resumption of HAART. One hundred and
sixty-seven patients were enrolled, and the median nadir CD4
count was 436 cells/µl and entry CD4 count 833 cells/µl. The
strategy was assessed as being ‘generally safe’ and patients
spent a median of 96 weeks off HAART. Three CDC B and
2 CDC C events occurred, all in patients with CD4 counts > 350
cells/µl. There were 5 deaths, none HIV-related; 3 of the deaths
were cardiovascular-related. Of the patients 28% needed to
restart HAART during the study period, and only nadir CD4
count was predictive of the need to re-initiate in a multivariate
analysis. The predictors of disease progression, death and CD4
decline in this cohort were a lower CD4 nadir and VL > 50
copies/ml at study entry.
STACCATO3
This study was conducted in Thailand, Switzerland and
Australia. Of the patients 80% were on ritonavir-boosted
saquinavir regimens. In this study the strategy was for patients
to stop HAART when the CD4  count was above 350 cells/µl,
but to restart when it dropped below 350 cells/µl (higher than
the threshold in other studies); 430 patients were randomised
to either continuous therapy (CT) or these STIs. Patients had to
have a VL < 50 copies/ml on entry. A third arm to the study
(one week on and one week off HAART) was prematurely
terminated because of a high virological failure rate. 
Patients were able to spend a median of 63% of study time off
HAART and there was no excess in drug resistance mutations
in the STI group. In contrast to SMART there were fewer drug
side-effects in the STI group: diarrhoea, neuropathy and self-
reported lipodystrophy were all less common in the STI arm.
Minor manifestations of HIV infection such as oral and vaginal
thrush and thrombocytopenia were more frequent in the STI
arm. There were no AIDS-defining illnesses in either arm and
there were 2 non-AIDS-related deaths, one in each arm.
At the end of the study continuous HAART was recommenced
for 12 - 24 weeks, and 92% (CT) v. 90% (STI) suppressed to a
VL < 50 copies/ml. There was little evidence that the STIs
predisposed to resistance (resistance mutations were detected
in around 2% of patients in both arms).
TRIVICAN4
This study was undertaken in Cote d'Ivoire. Patients on HAART
with CD4 counts > 350 cells/µl, VL < 300 copies/ml and CD4
nadir > 150 cells/µl were enrolled. The study compared
continuous therapy with two STI strategies, a CD4-guided
strategy (treatment interrupted at CD4 > 350 cells/µl and
restarted when it dropped below 250 cells/µl) and a 2-month-
off/4-month-on therapy strategy. Endpoints were death and
serious morbidity (WHO stage 3 or 4 conditions). At the interim
analysis the DSMB recommended stopping the CD4-guided STI
arm, and the analysis of this arm versus continuous therapy
was presented at CROI. Patients in the study had a median
nadir CD4 of 272 cells/µl and median CD4 at entry of 460
cells/µl. A more than 2-fold higher rate of serious morbidity
was demonstrated in the STI arm (IRR 2.6, 95% CI 1.3 -5.6).
This was mainly accounted for by invasive bacterial infections
(IRR 15.9, 95% CI 2.6 - 64.8). The common bacterial infections
were Salmonella typhi and Streptococcus pneumoniae. There
was also a non-significant trend to more tuberculosis and
oropharyngeal candida in the STI arm. There were more
hospitalisations and outpatient visits in the STI arm. There
were no significant differences between the two arms in terms
of mortality, drug side-effects or emergence of viral resistance.
ISS PART5
There were two arms in this study: a continuous treatment
arm and an STI arm in which there were planned interruptions
of 1, 1, 2, 2 and 3 months with a 3-month period of
continuous HAART in between each of these interruptions;
70% of patients were on non-nucleoside reverse transcriptase
inhibitor (NNRTI)-based regimens, and when interrupting they
stopped the NNRTI 3 - 6 days before the other drugs. Those on
protease inhibitor (PI) regimens were mainly on unboosted PIs.
All patients were on their first regimen and all had VLs < 400
copies/ml at study entry. The mean CD4 at study entry in the
STI arm was 714 cells/µl and the mean CD4 nadir 418 cells/µl.
The primary endpoint was the proportion of patients with CD4
> 500 cells/µl at 24 months. More patients achieved the
primary endpoint in the CT arm (87% v. 69%), making the STI
strategy inferior to continuous treatment in this regard. There
were more protocol discontinuations in the STI arm. Rates of
virological failure (defined as VL > 400 copies/ml at 24
months) were the same in both arms (8% in CT arm v. 9% in
STI arm). Thirty per cent of patients in the STI arm
demonstrated at least one resistance mutation during
treatment interruptions and these were associated with a
greater risk of virological failure. The emergence of resistance
mutations was associated with the presence of archived
mutations in proviral DNA at baseline and the use of
unboosted PIs. The investigators concluded that potential STI
candidates were patients with:
■ high pre-HAART CD4
■ absence of archived mutations
■ absence of residual viral replication (VL < 2.5 copies/ml),
■ and not on unboosted PIs.
There were 14 serious adverse events in each arm – none were
drug side-effects.
WINDOW-ANRS 1066
Patients with nadir CD4 > 100 cells/µl on HAART with
CD4 > 450 cells/µl and VL < 200 copies/ml for at least 6
months were randomly assigned to either continuous therapy
or an 8 week-on/8 week-off strategy for 96 weeks. Patients on
nevirapine were excluded and if patients were on efavirenz
this was stopped 7 days before other drugs in their regimen.
At baseline the median CD4 was 741 cells/µl and nadir 280
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cells/µl and 8% had AIDS. The primary outcome was
immunological failure defined as reaching CD4 < 300 cells/µl;
3.6% v. 1.5% reached this primary endpoint, demonstrating
that this STI strategy was not inferior to continuous therapy in
this regard. The median loss of CD4 cells was 155 cells/µl in
the STI arm over 96 weeks. The interruption strategy was also
clinically safe. There were 2 HIV unrelated deaths (1 violent
and 1 from alcoholic cirrhosis) in the STI arm and no AIDS-
defining illnesses in either arm. There was no difference in
drug side-effect rates between the two arms. More patients in
the STI arm had VL > 400 copies/ml at 96 weeks (19% v. 10%,
p = 0.02). There was no significant difference in resistance
patterns in patients experiencing virological failure between
the two arms. Over the 96 weeks those in the STI arm were
spared 49% of drug exposure.
OTHER ISSUES TO CONSIDER
STIs are also associated with thrombocytopenia (< 5% in all 
studies) and acute retroviral syndrome (up to maximum 6% in
the Staccato study). 
Nadir CD4 count is the best predictor of how long patients can
spend off HAART. Pre-HAART CD4 nadir was the only
independent predictor of time off HAART in ACTG 5170.
After stopping HAART the CD4 declines to the pre-HAART
nadir within weeks. The ACTG 5170 study demonstrated a
rapid decrease in CD4 count in the first 2 months after
stopping HAART (by 198 cells/µl), reflecting a fall back to pre-
HAART nadir. Thereafter there was a more gradual decline (1.7
cells/µl/week), reflecting natural progression of immuno-
suppression. There is also a rapid VL rebound after stopping
HAART: VL setpoint was reached 4 weeks after stopping
HAART in this study. 
Another important issue to consider when interrupting HAART
is the potential for the development of viral resistance. This
applies particularly to interruptions in an NNRTI regimen, as
NNRTIs have much longer half-lives than NRTIs and therefore
persist in the plasma after the regimen is stopped, resulting in
effective monotherapy and the selection of NNRTI drug
resistance mutations. To help avoid this it is advisable to
continue the NRTIs for 5 - 10 days after the NNRTI is stopped
to ‘cover the NNRTI tail’.
On a public health level it must also be considered that STIs, by
resulting in episodes of viraemia, may contribute to an
increased risk of HIV transmission. Another issue to consider is
that in patients with chronic hepatitis B, stopping HAART
regimens that contain lamivudine (3TC), emtricitabine (FTC) or
tenofovir may result in hepatitis flares and is therefore not
advised.
CONCLUSION
Key messages to emerge from these studies are:
■ The largest study on this issue (SMART) demonstrated a
clear increase in the risk of morbidity and mortality using
an STI strategy. This particular STI strategy is therefore not
advised in clinical practice. Other studies have shown STI
to be safe, and this may result from differences in study
design and patient population. Further studies to confirm
whether STI strategies may be safe in less immunologically
advanced patients using more conservative strategies are
needed. Until then they are generally not advised in clinical
practice.
■ Some feel that STIs may still have a role in patients who
started HAART early with CD4 counts higher than 350
cells/µl and where a threshold of 350 cells/µl for
recommencing HAART during STI is set. Certain studies
(Staccato and ACTG 5170) support this. However, in the
SMART study even patients with a CD4 nadir > 400 cells/µl
had excess morbidity/mortality in the STI arm.
■ It is important to remember that most of the HIV-related
morbidity associated with STIs in the SMART study
occurred when the CD4 was between 250 and 350 cells/µl,
and on the basis of SMART STIs that allow CD4 decline into
this range therefore seem inadvisable.
■ The best predictor of outcome using an STI strategy is
nadir CD4. STIs are most risky in patients with low CD4
nadir. 
■ The setting is also an important consideration.  The one
study done in Africa showed unique risks, in particular
invasive bacterial infections. 
■ An unexpected outcome of the SMART study was an
increase in cardiovascular, hepatic and renal complications
in the STI arm. It was speculated that HIV replication and
the resulting immune activation during STIs may play a
role in inflammation-mediated cardiovascular effects.
■ Most studies showed no increased risk of viral resistance
using an STI strategy apart from ISS PART. The HAART
regimens patients were on and the staggering method of
stopping drugs may have influenced this. In the ISS PART
study interruptions of an unboosted PI regimen was a
particular risk factor for resistance.
It is important to note that the risks associated with
progression during STI may well be different from those in
naïve patients, and the findings above therefore do not apply
to decisions about when to start HAART in naïve patients. The
data above are useful for clinicians managing a patient on
HAART who requests a self-initiated ‘drug holiday’. There are
many findings here that allow for an evidence-based
discussion regarding the risks associated with this for an
individual patient. Clearly the nadir CD4 is the most important
factor to consider in such discussions. 
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